Second Japan Diovan study found compromised
This article was originally published in Scrip
Executive Summary
Controversy over the integrity of data from large-scale clinical studies in Japan for Novartis's blockbuster antihypertensive Diovan (valsartan) continues, with an investigation by a second university in the country determining that the "scientific reliability" of a published paper has been compromised.